logo

Mirati Therapeutics, Inc. (MRTX)



Trade MRTX now with
  Date
  Headline
5/18/2020 4:16:53 PM Mirati Therapeutics Appoints Joseph Leveque As Chief Medical Officer
5/15/2020 9:01:42 AM Mirati Therapeutics To Present Preclinical Data From Investigational Pipeline Of Novel Therapeutics
2/25/2020 8:13:29 AM Mirati Therapeutics Q4 Net Loss $72.4 Mln Or $1.83/Shr Vs Loss Of $28.3 Mln Or $0.87/Shr Last Year
2/19/2020 8:37:08 AM Mirati Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule
1/14/2020 4:02:44 PM Mirati Therapeutics Closes Public Offering Of 3.54 Mln Shares Of Its Common Stock
1/9/2020 10:06:24 PM Mirati Therapeutics Prices Underwritten Public Offering Of 3.08 Mln Shares At $97.50/shr
1/8/2020 4:07:31 PM Mirati Therapeutics Announces Proposed Public Offering Of Common Stock
8/15/2019 4:35:20 PM Mirati Therapeutics Appoints Jenny Gizzi As VP, Human Resources
7/1/2019 4:43:13 PM Mirati Therapeutics Appointa Julie Cherrington To Board Of Directors
6/27/2019 4:21:53 PM Mirati Therapeutics Closes Public Offering Of Common Stock
6/25/2019 8:33:54 AM Mirati Therapeutics Prices Public Offering Of 2.10 Mln Shares At $97.00/shr
6/24/2019 4:02:35 PM Mirati Therapeutics Announces Proposed Public Offering Of Common Stock
4/29/2019 4:12:58 PM Mirati Therapeutics Q1 Loss/share $1.17 Vs. Loss $0.51 Year Ago
2/28/2019 4:28:26 PM Mirati Therapeutics Q4 Loss/share $0.87 Vs. Loss $0.67 Year Ago